Bcor insufficiency promotes initiation and progression of myelodysplastic syndrome. Mus musculus

BCOR, encoding BCL-6 co-repressor (BCOR), is X-linked and targeted by somatic mutations in various hematological malignancies including myelodysplastic syndrome (MDS). We previously reported that mice lacking Bcor exon 4 (Bcor dE4/y) in the hematopoietic compartment developed NOTCH-dependent acute T-cell lymphoblastic leukemia (T-ALL). Here, we analyzed mice lacking Bcor exons 9 and 10 (Bcor dE9-10/y), which express a carboxyl-terminal truncated BCOR that fails to interact with core effector components of polycomb repressive complex (PRC) 1.1. Bcor dE9-10/y mice developed lethal T-ALL in a similar manner to Bcor dE4/y mice, while Bcor dE9-10 hematopoietic cells showed a growth advantage in the myeloid compartment that was further enhanced by the concurrent deletion of Tet2. Tet2d/dBcor dE9-10 mice developed lethal MDS with progressive anemia and leukocytopenia, inefficient hematopoiesis, and the morphological dysplasia of blood cells. Tet2d/dBcor dE9-10 MDS cells reproduced MDS or evolved into lethal MDS/MPN in secondary recipients. Transcriptional profiling revealed the de-repression of myeloid regulator genes of the Cebp family and Hoxa cluster genes in Bcor dE9-10 progenitor cells and the activation of p53 target genes specifically in MDS erythroblasts where massive apoptosis occurred. Our results reveal a tumor suppressor function of BCOR in myeloid malignancies and highlight the impact of Bcor insufficiency on the initiation and progression of MDS.